Aset Therapeutics, Inc.
Aset Therapeutics, Inc. is listed today as Black Diamond Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2019 | $85 M | No. 4 | $50 to $250 million | equity | SEC | |
| Dec 2018 | $44 M | No. 3 | $10 to $50 million | equity | SEC | |
| Aug 2018 | $5 M | No. 2 | $2 to $10 million | equity | SEC | |
| Mar 2017 | $12 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Black Diamond Therapeutics, Inc., its revenue in fiscal 2025 came from these business segments: Reportable segment $70 million (100%).
Annual report (SEC XBRL) · Dec 2025
Aset Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2019).
SEC Form D · Dec 2019
The industry group it chose in its notices: Biotechnology.
SEC Form D · Dec 2019
Products and services#
No products or services of Aset Therapeutics, Inc. are on record.
Investors#
12 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| David M. Epstein | Person | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Deerfield Mgmt L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Deerfield Partners, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Nea 16 GP, LLC | Other | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| NEA Partners 16, L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| New Enterprise Associates 16, L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Versant Vantage I, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Versant Venture Capital VI, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Versant Voyageurs I, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Versant Voyageurs I Parallel, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 28 investors.
Largest shareholders today
Institutions holding Black Diamond Therapeutics, Inc. shares, as of Sep 30, 2026.
- NEA Management Company, LLC$8 M7.74%
- BlackRock, Inc.$8 M7.48%
- T. Rowe Price Investment Management, Inc.$7 M6.83%
- Acadian Asset Management LLC$4 M4.09%
- Vanguard Capital Management LLC$4 M3.70%
- Bank Of America Corp /de/$4 M3.56%
- Defilade Capital Management, L.P.$3 M3.08%
- Renaissance Technologies LLC$3 M2.87%
- Geode Capital Management, LLC$2 M2.17%
- Marshall Wace, LLP$2 M2.05%
- Connor, Clark & Lunn Investment Management Ltd.$2 M1.95%
- Dimensional Fund Advisors LP$2 M1.66%
- State Street Corp$2 M1.64%
- AQR Capital Management LLC$2 M1.55%
- Morgan Stanley$1 M1.35%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Brent M. Hatzis-Schoch | Executive officer | Dec 2019 |
| Christopher M. Roberts | Executive officer | Dec 2019 |
| David M. Epstein | Executive officer | Dec 2019 |
| Thomas M. Leggett | Executive officer | Dec 2019 |
| Brent E. Hatzis-Schoch | Executive officer | Jul 2019 |
| Elizabeth M. Buck | Executive officer | Jul 2019 |
| Fang M. Ni | Executive officer | Jul 2019 |
| Elizabeth E. Buck | Executive officer | Aug 2018 |
| David M Epstein | Executive officer | Jan 2018 |
| Elizabeth M Buck | Executive officer | Jan 2018 |
| Alexander M. Mayweg | Director | Dec 2019 |
| Ali M. Behbahani | Director | Dec 2019 |
| Bradley M. Bolzon | Director | Dec 2019 |
| David M. Epstein | Director | Dec 2019 |
| Garry M. Menzel | Director | Dec 2019 |
| Rajeev M. Shah | Director | Dec 2019 |
| Samarth M. Kulkarni | Director | Dec 2019 |
| Garry E. Menzel | Director | Jul 2019 |
| Alexander M Mayweg | Director | Jan 2018 |
| Brad E Bolzon | Director | Jan 2018 |
| David M Epstein | Director | Jan 2018 |
| Garry E Menzel | Director | Jan 2018 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.